Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

Breast Cancer Research and Treatment

Volumn 119, Issue 1, 2010, Pages 119-126

  De Ronde, Jorma J ^a   Hannemann, Juliane ^a   Halfwerk, Hans ^a   Mulder, Lennart ^a   Straver, Marieke E ^a   Vrancken Peeters, Marie Jeanne T F D ^a   Wesseling, Jelle ^a   Van De Vijver, Marc ^a   Wessels, Lodewyk F A ^a   Rodenhuis, Sjoerd ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer subtypes; Clinical subtypes; Intrinsic genes; Molecular subtypes; Neoadjuvant chemotherapy response

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MESSENGER RNA; PACLITAXEL; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HORMONE RELEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR TYPING; NETHERLANDS; ONCOGENE NEU; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REMISSION; RNA ANALYSIS; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; BIOPSY; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MODELS, GENETIC; PREOPERATIVE PERIOD; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER;

EID: 72449204608     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0499-6     Document Type: Article

References (42)

1. EA Rakha IO Ellis 2007 An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens J Clin Pathol 60 1300 1306 10.1136/jcp.2006.045377 1:STN:280:DC%2BD2sjgtlOrsA%3D%3D 17630399 (Pubitemid 350247244)
2. H Denley SE Pinder CW Elston AH Lee IO Ellis 2001 Preoperative assessment of prognostic factors in breast cancer J Clin Pathol 54 20 24 10.1136/jcp.54.1.20 1:STN:280:DC%2BD3M7ntFClsg%3D%3D 11271783 (Pubitemid 32048290)
3. V Valero AU Buzdar GN Hortobagyi 1996 Locally advanced breast cancer Oncologist 1 8 17 10387963
4. RI Nicholson SR Johnston 2005 Endocrine therapy-current benefits and limitations Breast Cancer Res Treat 93 Suppl 1 S3 S10 10.1007/s10549-005-9036-4 1:CAS:528:DC%2BD2MXhtFCrtb3O 16247594
5. S Hayashi Y Yamaguchi 2008 Estrogen signaling pathway and hormonal therapy Breast Cancer 15 256 261 10.1007/s12282-008-0070-z 18818989
6. E Tokunaga E Oki K Nishida T Koga A Egashira M Morita, et al. 2006 Trastuzumab and breast cancer: developments and current status Int J Clin Oncol 11 199 208 10.1007/s10147-006-0575-4 1:CAS:528:DC%2BD28XntVGju7k%3D 16850126 (Pubitemid 44087118)
7. JS Ross JA Fletcher KJ Bloom GP Linette J Stec WF Symmans, et al. 2004 Targeted therapy in breast cancer: the HER-2/neu gene and protein Mol Cell Proteomics 3 379 398 10.1074/mcp.R400001-MCP200 1:CAS:528:DC%2BD2cXivFCksLs%3D 14762215 (Pubitemid 38702091)
8. Nielsen DL, Andersson M, Kamby C. (2008) HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 35:121-136
9. PL Nguyen AG Taghian MS Katz A Niemierko RF Abi Raad WL Boon, et al. 2008 Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy J Clin Oncol 26 2373 2378 10.1200/JCO.2007.14.4287 18413639
10. AM Gown 2008 Current issues in ER and HER2 testing by IHC in breast cancer Mod Pathol 21 Suppl 2 S8 S15 10.1038/modpathol.2008.34 1:CAS:528:DC%2BD1cXltFehsr8%3D 18437174 (Pubitemid 351592775)
11. CM Ellis MJ Dyson TJ Stephenson EL Maltby 2005 HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques J Clin Pathol 58 710 714 10.1136/jcp.2004.023424 1:CAS:528:DC%2BD2MXntV2lu74%3D 15976337 (Pubitemid 40956824)
12. M Dowsett WM Hanna M Kockx F Penault-Llorca J Ruschoff T Gutjahr, et al. 2007 Standardization of HER2 testing: results of an international proficiency-testing ring study Mod Pathol 20 584 591 10.1038/modpathol.3800774 17396141 (Pubitemid 46632000)
13. A Sanchez-Munoz AM Garcia-Tapiador E Martinez-Ortega R Duenas-Garcia A Jaen-Morago AL Ortega-Granados, et al. 2008 Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Clin Transl Oncol 10 646 653 10.1007/s12094-008-0265-y 1:CAS:528:DC%2BD1cXhsVyms7nO 18940745
14. C Desmedt B Haibe-Kains P Wirapati M Buyse D Larsimont G Bontempi, et al. 2008 Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes Clin Cancer Res 14 5158 5165 10.1158/1078-0432.CCR- 07-4756 1:CAS:528:DC%2BD1cXpslKgur4%3D 18698033
15. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D 10963602 (Pubitemid 30671230)
16. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci U S A 100 8418 8423 10.1073/pnas.0932692100 1:CAS:528:DC%2BD3sXlsFGntLk%3D 12829800 (Pubitemid 36842560)
17. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 10869 10874 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D 11553815 (Pubitemid 32878711)
18. Z Hu C Fan DS Oh JS Marron X He BF Qaqish, et al. 2006 The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics 7 96 10.1186/1471-2164-7-96 16643655 (Pubitemid 43786485)
19. CE Loo HJ Teertstra S Rodenhuis MJ van de Vijver J Hannemann SH Muller, et al. 2008 Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results AJR Am J Roentgenol 191 1331 1338 10.2214/AJR.07.3567 18941065
20. P Chollet S Amat H Cure M de Latour G le Bouedec MA Mouret-Reynier, et al. 2002 Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer Br J Cancer 86 1041 1046 10.1038/sj.bjc.6600210 1:STN:280:DC%2BD383hs1KgsA%3D%3D 11953845 (Pubitemid 34441058)
21. S Dawood K Broglio SW Kau R Islam WF Symmans TA Buchholz, et al. 2008 Prognostic value of initial clinical disease stage after achieving pathological complete response Oncologist 13 6 15 10.1634/theoncologist.2007-0107 18245008 (Pubitemid 351206692)
22. V Guarneri K Broglio SW Kau M Cristofanilli AU Buzdar V Valero, et al. 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037 1044 10.1200/JCO.2005.02.6914 16505422 (Pubitemid 46638799)
23. HM Kuerer LA Newman TL Smith FC Ames KK Hunt K Dhingra, et al. 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 1:CAS:528:DyaK1MXht1Wmur4%3D 10080586
24. MR Machiavelli AO Romero JE Perez JA Lacava ME Dominguez R Rodriguez, et al. 1998 Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma Cancer J Sci Am 4 125 131 1:STN:280: DyaK1c7ptlGrsA%3D%3D 9554929
25. T Shien C Shimizu K Seki T Shibata T Hojo M Ando, et al. 2009 Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome Breast Cancer Res Treat 113 307 313 10.1007/s10549-008-9935-2 18286370
26. J Hannemann HM Oosterkamp CA Bosch A Velds LF Wessels C Loo, et al. 2005 Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer J Clin Oncol 23 3331 3342 10.1200/JCO.2005.09.077 1:CAS:528:DC%2BD2MXlsVyiu70%3D 15908647 (Pubitemid 46243477)
27. IO Ellis M Galea N Broughton A Locker RW Blamey CW Elston 1992 Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up Histopathology 20 479 489 1:STN:280:DyaK383pvFartw%3D%3D 1607149
28. Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, Pruneri G et al. (2008) Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 116:359-369
29. J Cohen 1960 A Coefficient of Agreement for Nominal Scales Educ Psychol Measur 20 37 46 10.1177/001316446002000104
30. NS Goldstein D Decker D Severson S Schell F Vicini J Margolis, et al. 2007 Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy Cancer 110 1687 1696 10.1002/cncr.22981 1:CAS:528:DC%2BD2sXht1GksLzN 17722109 (Pubitemid 47557293)
31. R Rouzier CM Perou WF Symmans N Ibrahim M Cristofanilli K Anderson, et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 10.1158/1078-0432.CCR-04-2421 1:CAS:528:DC%2BD2MXos1Cjs7k%3D 16115903 (Pubitemid 41170290)
32. F Andre C Mazouni C Liedtke SW Kau D Frye M Green, et al. 2008 HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer Breast Cancer Res Treat 108 183 190 10.1007/s10549-007-9594-8 1:CAS:528:DC%2BD1cXitleqsbs%3D 17468948 (Pubitemid 351311360)
33. JS Parker M Mullins MC Cheang S Leung D Voduc T Vickery, et al. 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 1160 1167 10.1200/JCO.2008.18.1370 19204204
34. AM Chen F Meric-Bernstam KK Hunt HD Thames ED Outlaw EA Strom, et al. 2005 Breast conservation after neoadjuvant chemotherapy Cancer 103 689 695 10.1002/cncr.20815 15641036 (Pubitemid 40216395)
35. R Kim A Osaki T Toge 2005 Current and future roles of neoadjuvant chemotherapy in operable breast cancer Clin Breast Cancer 6 223 232 10.3816/CBC.2005.n.024 16137432
36. F Peintinger WF Symmans AM Gonzalez-Angulo JC Boughey AU Buzdar TK Yu, et al. 2006 The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy Cancer 107 1248 1254 10.1002/cncr.22111 16862596 (Pubitemid 44452773)
37. C Shimizu M Ando T Kouno N Katsumata Y Fujiwara 2007 Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer Jpn J Clin Oncol 37 1 8 10.1093/jjco/hyl122 17202251 (Pubitemid 47090717)
38. ME Straver JC van Adrichem EJ Rutgers S Rodenhuis SC Linn CE Loo, et al. 2008 [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]Neoadjuvante systemische therapie bij het primair operabel mammacarcinoom: meer voordelen dan alleen borstsparende behandeling Ned Tijdschr Geneeskd 152 2519 2525 1:STN:280:DC%2BD1cjos1ygsg%3D%3D 19055260
39. A Thomas R Ohlinger M Hauschild A Mustea JU Blohmer S Kummel 2006 Options and limits of surgery after pre-operative chemotherapy in breast cancer Anticancer Res 26 1677 1682 1:CAS:528:DC%2BD28XktVGqsL8%3D 16617561
40. R Nahta D Yu MC Hung GN Hortobagyi FJ Esteva 2006 Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer Nat Clin Pract Oncol 3 269 280 10.1038/ncponc0509 1:CAS:528:DC%2BD28Xltlagtbg%3D 16683005 (Pubitemid 43731112)
41. K Berns HM Horlings BT Hennessy M Madiredjo EM Hijmans K Beelen, et al. 2007 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 395 402 10.1016/j.ccr.2007.08.030 1:CAS:528:DC%2BD2sXht1ais7zL 17936563 (Pubitemid 47539306)
42. F Peintinger AU Buzdar HM Kuerer JA Mejia C Hatzis AM Gonzalez-Angulo, et al. 2008 Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab Ann Oncol 19 2020 2025 10.1093/annonc/mdn427 1:STN:280:DC%2BD1cjlsFChtw%3D%3D 18667396